{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:36:07Z","timestamp":1782941767534,"version":"3.54.5"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ejps.2019.105008","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T11:23:30Z","timestamp":1562844210000},"page":"105008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Pemetrexed-conjugated hyaluronan for the treatment of malignant pleural mesothelioma"],"prefix":"10.1016","volume":"138","author":[{"given":"Yuki","family":"Amano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma L.","family":"Sakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1589-8242","authenticated-orcid":false,"given":"Taichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2019.105008_bb0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0083-6729(08)00409-3","article-title":"Regulation of human dihydrofolate reductase activity and expression","volume":"79","author":"Abali","year":"2008","journal-title":"Vitam. Horm."},{"issue":"Pt A","key":"10.1016\/j.ejps.2019.105008_bb0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jconrel.2015.10.019","article-title":"Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed","volume":"220","author":"Ando","year":"2015","journal-title":"J. Control. Release"},{"issue":"Suppl. 2","key":"10.1016\/j.ejps.2019.105008_bb0015","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0169-5002(07)70424-5","article-title":"Optimising survival in malignant mesothelioma","volume":"57","author":"Baas","year":"2007","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.ejps.2019.105008_bb0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0304-3835(99)00334-1","article-title":"Cytotoxic and antitumor effect of fibrinogen-methotrexate conjugate","volume":"148","author":"Boraty\u0144ski","year":"2000","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.ejps.2019.105008_bb0025","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/(SICI)1097-4636(199911)47:2<152::AID-JBM5>3.0.CO;2-I","article-title":"New strategy for chemical modification of hyaluronic acid: preparation of functionalized derivatives and their use in the formation of novel biocompatible hydrogels","volume":"47","author":"Bulpitt","year":"1999","journal-title":"J. Biomed. Mater. Res."},{"key":"10.1016\/j.ejps.2019.105008_bb0030","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jconrel.2010.04.006","article-title":"Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer","volume":"146","author":"Cai","year":"2010","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.ejps.2019.105008_bb0035","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1021\/bc0499174","article-title":"Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX","volume":"15","author":"Chau","year":"2004","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejps.2019.105008_bb0040","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1083\/jcb.200302098","article-title":"The liberation of CD44","volume":"161","author":"Cichy","year":"2003","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/j.ejps.2019.105008_bb0045","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1515\/acph-2016-0001","article-title":"Methods for preliminary determination of pemetrexed in macromolecular drug-carrier systems","volume":"66","author":"Ciekot","year":"2016","journal-title":"Acta Pharma."},{"issue":"3","key":"10.1016\/j.ejps.2019.105008_bb0050","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.lungcan.2013.09.016","article-title":"Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma","volume":"82","author":"Creaney","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejps.2019.105008_bb0055","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejps.2015.09.015","article-title":"Encapsulation in a rapid-release liposomal formulation enhances the anti-tumor efficacy of pemetrexed in a murine solid mesothelioma-xenograft model","volume":"81","author":"Eldin","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.ejps.2019.105008_bb0060","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s11030-017-9776-1","article-title":"Synthesis, characterization and molecular docking studies of thiouracil derivatives as potent thymidylate synthase inhibitors and potential anticancer agents","volume":"21","author":"El-Naggar","year":"2017","journal-title":"Mol. Divers."},{"issue":"5","key":"10.1016\/j.ejps.2019.105008_bb0065","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00595-013-0674-6","article-title":"Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer","volume":"44","author":"Emoto","year":"2014","journal-title":"Surg. Today"},{"issue":"5","key":"10.1016\/j.ejps.2019.105008_bb0070","doi-asserted-by":"crossref","first-page":"e705","DOI":"10.1016\/j.cllc.2018.05.001","article-title":"A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: a study protocol","volume":"19","author":"Fujimoto","year":"2018","journal-title":"Clin. Lung Cancer"},{"issue":"11","key":"10.1016\/j.ejps.2019.105008_bb0075","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1517\/14656566.2013.802774","article-title":"Pemetrexed for the treatment of non-small cell lung cancer","volume":"14","author":"Genova","year":"2013","journal-title":"Expert. Opin. Pharmacother."},{"issue":"2","key":"10.1016\/j.ejps.2019.105008_bb0080","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1021\/bc0501855","article-title":"Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines","volume":"17","author":"Gurdag","year":"2006","journal-title":"Bioconjug. Chem."},{"issue":"4","key":"10.1016\/j.ejps.2019.105008_bb0085","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000337060","article-title":"Novel intrapleural therapies for malignant diseases","volume":"83","author":"Haas","year":"2012","journal-title":"Respiration"},{"issue":"4","key":"10.1016\/j.ejps.2019.105008_bb0090","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1634\/theoncologist.6-4-363","article-title":"Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors","volume":"6","author":"Hanauske","year":"2001","journal-title":"Oncologist"},{"issue":"2\u20133","key":"10.1016\/j.ejps.2019.105008_bb0095","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0079-6107(97)00027-8","article-title":"The intrinsic viscosity of biological macromolecules. Progress in measurement, interpretation and application to structure in dilute solution","volume":"68","author":"Harding","year":"1997","journal-title":"Prog. Biophys. Mol. Biol."},{"issue":"13","key":"10.1016\/j.ejps.2019.105008_bb0100","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1016\/j.bmc.2009.04.063","article-title":"Novel hyaluronic acid-methotrexate conjugates for osteoarthritis treatment","volume":"17","author":"Homma","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2019.105008_bb0105","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1124\/dmd.107.019299","article-title":"Characterization and comparative studies of zebrafish and human recombinant dihydrofolate reductases\u2013inhibition by folic acid and polyphenols","volume":"36","author":"Kao","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.ejps.2019.105008_bb0110","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1021\/bc8000485","article-title":"Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity","volume":"19","author":"Lee","year":"2008","journal-title":"Bioconjug. Chem."},{"issue":"4","key":"10.1016\/j.ejps.2019.105008_bb0115","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1054\/bjoc.2001.1922","article-title":"Hyaluronan production increases the malignant properties of mesothelioma cells","volume":"85","author":"Li","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ejps.2019.105008_bb0120","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ejmech.2011.11.027","article-title":"Dendrimer-based multivalent methotrexates as dual acting nanoconjugates for cancer cell targeting","volume":"47","author":"Li","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2019.105008_bb0125","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12931-017-0546-5","article-title":"CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives","volume":"18","author":"Lourdes","year":"2017","journal-title":"Respir. Res."},{"issue":"7","key":"10.1016\/j.ejps.2019.105008_bb0130","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.3109\/10717544.2015.1033794","article-title":"Antitumor and antimetastatic effects of pemetrexed-loaded targeted nanoparticles in B16 bearing mice","volume":"23","author":"Lu","year":"2016","journal-title":"Drug Deliv."},{"issue":"5","key":"10.1016\/j.ejps.2019.105008_bb0135","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1021\/bc9900338","article-title":"Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate","volume":"10","author":"Luo","year":"1999","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejps.2019.105008_bb0140","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1023\/A:1015170907274","article-title":"Targeted delivery of doxorubicin by HPMA copolymerhyaluronan bioconjugates","volume":"19","author":"Luo","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.105008_bb0145","doi-asserted-by":"crossref","unstructured":"Misra, S., Hascall V. C., Markwald, R. R., Ghatak, S., 2015. Interactions between Hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer. Front. Immunol. 6, 6, 201.","DOI":"10.3389\/fimmu.2015.00201"},{"key":"10.1016\/j.ejps.2019.105008_bb0150","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1021\/bi050160t","article-title":"Kinetics of the inhibition of bovine liver dihydrofolate reductase by tea catechins: origin of slow-binding inhibition and pH studies","volume":"44","author":"Navarro-Per\u00e1n","year":"2005","journal-title":"Biochemistry"},{"issue":"2A","key":"10.1016\/j.ejps.2019.105008_bb0155","first-page":"1135","article-title":"Antitumor properties and toxicity of dextran-methotrexate conjugates are dependent on the molecular weight of the carrier","volume":"26","author":"Nevozhay","year":"2006","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.ejps.2019.105008_bb0160","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1021\/acs.bioconjchem.5b00674","article-title":"Production of cisplatin-incorporating Hyaluronan nanogels via chelating ligand-metal coordination","volume":"27","author":"Ohta","year":"2016","journal-title":"Bioconjug. Chem."},{"issue":"9","key":"10.1016\/j.ejps.2019.105008_bb0165","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1021\/acs.molpharmaceut.7b00349","article-title":"Intraperitoneal delivery of cisplatin via a Hyaluronan-based nanogel\/in situ cross-linkable hydrogel hybrid system for peritoneal dissemination of gastric cancer","volume":"14","author":"Ohta","year":"2017","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.ejps.2019.105008_bb0170","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/mabi.201300383","article-title":"Tailored doxorubicin-hyaluronan conjugate as a potent anticancer glyco-drug: an alternative to prodrug approach","volume":"14","author":"Oommen","year":"2014","journal-title":"Macromol. Biosci."},{"issue":"1","key":"10.1016\/j.ejps.2019.105008_bb0175","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1021\/bm700843m","article-title":"New amphiphilic lactic acid oligomer-hyaluronan conjugates: synthesis and physicochemical characterization","volume":"9","author":"Pravata","year":"2008","journal-title":"Biomacromolecules"},{"issue":"4","key":"10.1016\/j.ejps.2019.105008_bb0180","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1021\/bc010098m","article-title":"Polyethylene glycol conjugates of methotrexate varying in their molecular weight from MW 750 to MW 40000: synthesis, characterization, and structure-activity relationships in vitro and in vivo","volume":"13","author":"Riebeseel","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejps.2019.105008_bb0185","first-page":"907","article-title":"Novel Hyaluronan formulation enhances the efficacy of boron neutron capture therapy for murine mesothelioma","volume":"3","author":"Sasai","year":"2016","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejps.2019.105008_bb0190","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/3-7643-7414-4_11","article-title":"Preclinical development of Alimta (Pemetrexed, LY231514), a multitargeted antifolate","volume":"63","author":"Schultz","year":"2005","journal-title":"Prog. Drug Res."},{"issue":"57","key":"10.1016\/j.ejps.2019.105008_bb0195","doi-asserted-by":"crossref","first-page":"7632","DOI":"10.1039\/c4cc02595d","article-title":"A hyaluronic acid-methotrexate conjugate for targeted therapy of rheumatoid arthritis","volume":"50","author":"Shin","year":"2014","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejps.2019.105008_bb0200","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1038\/s41598-018-21435-5","article-title":"Optimized peptide based inhibitors targeting the dihydrofolate reductase pathway in cancer","volume":"8","author":"Singh","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2019.105008_bb0205","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0167-4838(86)90067-1","article-title":"Mechanism of inhibition of dihydrofolate reductases from bacterial and vertebrate sources by various classes of folate analogues","volume":"869","author":"Stone","year":"1986","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.ejps.2019.105008_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcb.24642","article-title":"Malignant mesothelioma: development to therapy","volume":"115","author":"Thompson","year":"2014","journal-title":"J. Cell. Biochem."},{"issue":"10","key":"10.1016\/j.ejps.2019.105008_bb0215","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1021\/mp300131t","article-title":"Reduced folate carrier independent internalization of PEGylated pemetrexed: a potential nanomedicinal approRch for breast cancer therapy","volume":"9","author":"Vandana","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2019.105008_bb0220","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1016\/S0021-9258(19)84524-6","article-title":"The enzymatic synthesis of thymidylate. I. Early steps in the purification of thymidylate synthetase of Escherichia coli","volume":"237","author":"Wahba","year":"1962","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.ejps.2019.105008_bb0225","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/glycob\/cwx039","article-title":"What is special about 200 kDa hyaluronan that activates hyaluronan receptor signaling?","volume":"27","author":"Weigel","year":"2017","journal-title":"Glycobiology"},{"issue":"38","key":"10.1016\/j.ejps.2019.105008_bb0230","doi-asserted-by":"crossref","first-page":"15180","DOI":"10.1073\/pnas.1308827110","article-title":"Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition","volume":"110","author":"Wibowo","year":"2013","journal-title":"PNAS"},{"issue":"27","key":"10.1016\/j.ejps.2019.105008_bb0235","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1016\/j.biomaterials.2006.04.043","article-title":"In situ cross-linkable hyaluronic acid hydrogels prevent post-operative abdominal adhesions in a rabbit model","volume":"27","author":"Yeo","year":"2006","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.ejps.2019.105008_bb0240","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1124\/mol.113.089110","article-title":"Enhanced receptor-mediated endocytosis and cytotoxicity of a folic acid-desacetylvinblastine monohydrazide conjugate in a pemetrexed-resistant cell line lacking folate-specific facilitative carriers but with increased folate receptor expression","volume":"85","author":"Zhao","year":"2014","journal-title":"Mol. Pharmacol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719302714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719302714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:47:25Z","timestamp":1760528845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098719302714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":48,"alternative-id":["S0928098719302714"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2019.105008","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pemetrexed-conjugated hyaluronan for the treatment of malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2019.105008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105008"}}